Crohn's disease - infliximab (review) and adalimumab: review decision - March 2011
The Institute proposed that the recommendations within the existing guidance should be incorporated, verbatim, within the ongoing clinical guideline on Crohn's disease: the management of Crohn's disease. TA187 will remain in existence alongside the clinical guideline and will be moved to the static guidance list.
During consultation, the majority of comments received by the Institute agreed with the proposal put forward. After consideration of all of the comments (attached as appendix A), the Institute's Guidance Executive has decided to proceed with the proposal and the guidance will be incorporated into the on-going clinical guideline and classed by technology appraisals as static guidance. This will preserve the funding direction associated with the technology appraisal.
Topics on the static list may be transferred back to the active list for further review consideration if new evidence becomes available that is likely to have a material effect on the last guidance issued.
This page was last updated: 08 March 2011